BioMarin Pharmaceutical Stock Price, News & Analysis (NASDAQ:BMRN)

$83.05 -0.95 (-1.13 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$83.05
Today's Range$81.20 - $86.31
52-Week Range$78.50 - $100.51
Volume2.13 million shs
Average Volume1.37 million shs
Market Capitalization$14.42 billion
P/E Ratio-91.26
Dividend YieldN/A
Beta1.71

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:BMRN
CUSIP09061G10
Phone+1-415-5066700

Debt

Debt-to-Equity Ratio0.41%
Current Ratio4.91%
Quick Ratio3.81%

Price-To-Earnings

Trailing P/E Ratio-91.2637362637363
Forward P/E Ratio-259.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.31 billion
Price / Sales11.10
Cash FlowN/A
Price / CashN/A
Book Value$16.08 per share
Price / Book5.16

Profitability

Trailing EPS($0.91)
Net Income$-630,210,000.00
Net Margins-8.91%
Return on Equity-3.18%
Return on Assets-2.12%

Miscellaneous

Employees2,293
Outstanding Shares175,620,000

BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its earnings results on Thursday, October, 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.06. The biotechnology company earned $334.18 million during the quarter, compared to analyst estimates of $347.38 million. BioMarin Pharmaceutical had a negative return on equity of 3.18% and a negative net margin of 8.91%. BioMarin Pharmaceutical's revenue was up 19.4% compared to the same quarter last year. During the same period last year, the business posted $0.02 earnings per share. View BioMarin Pharmaceutical's Earnings History.

When will BioMarin Pharmaceutical make its next earnings announcement?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for BioMarin Pharmaceutical.

Where is BioMarin Pharmaceutical's stock going? Where will BioMarin Pharmaceutical's stock price be in 2018?

20 equities research analysts have issued 12 month price targets for BioMarin Pharmaceutical's shares. Their forecasts range from $89.00 to $150.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $113.63 in the next twelve months. View Analyst Ratings for BioMarin Pharmaceutical.

What are Wall Street analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:

  • 1. According to Zacks Investment Research, "BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, backed by strong underlying patient demand trends. BioMarin expects sustained growth in both the drugs. Brineura’s earlier-than-expected approval was also a huge boost for BioMarin. Its impressive rare-disease pipeline is also progressing well with approval for pegvaliase expected in 2018. The stock has slightly outperformed the industry in the past one year. However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due to infrequent ordering patterns from some countries, mainly Brazil. Nonetheles, loss estimates have narrowed ahead of the company’s Q4 earnings result. BioMarin also has a positive record of earnings surprises in the recent quarters." (1/17/2018)
  • 2. Cowen Inc analysts commented, "New data include 52 wk follow-up on all patients at BMN270’s 6e13 vg/kg dose, and." (7/11/2017)
  • 3. Wedbush analysts commented, "The Wedbush View: While we see meaningful clinical, regulatory and commercial progress this year, we remain NEUTRAL on BMRN as we believe the stock is relatively expensive as it consistently trades at the top of peers." (5/8/2017)
  • 4. Jefferies Group LLC analysts commented, "Narrower 1Q GAAP net loss reflects higher revenue & lower OpEx (non- GAAP income of $35M). Next clinical update includes BMN 270 data at ISTH on 7/8-7/13/17." (5/5/2017)
  • 5. JPMorgan Chase & Co. analysts commented, "By Lotus Inventory Impacting Margins In Q1, all rev lines came in above expectations. While Med-Surg has been a consistent outperformer of late, CRM upside was another bright spot. The strong growth came against a tough comp. Headline margins were disappointing due to a spate of issues including the Lotus recall (not surprising), Fuse scope losses (somewhat more surprising) and litigation charges (also not surprising). The Lotus and Fuse charges are not expected to recur; excluding these, we view margins as fairly in-line. While the revenue raise positions BSX shares more favorably in our view, we continue to see the potential for risk around Lotus. While we expect strong data at EuroPCR, we wonder if mgmt’s FDA timelines are aggressive as we would think the FDA might ask for meaningful additional clinical work on the new delivery system following the EU recall. We remain positive on BSX’s underlying fundamentals but feel its current P/E valuation is appropriate until Lotus issues are entirely resolved or Symetis closes and sales ramp." (5/1/2017)

Who are some of BioMarin Pharmaceutical's key competitors?

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:

  • Jean-Jacques Bienaime, Chairman of the Board, Chief Executive Officer (Age 63)
  • Daniel Keith Spiegelman, Chief Financial Officer, Executive Vice President (Age 58)
  • G. Eric Davis, Executive Vice President, General Counsel, Secretary (Age 46)
  • Jeff Robert Ajer, Executive Vice President, Chief Commercial Officer (Age 55)
  • Robert A. Baffi Ph.D., Executive Vice President - Technical Operations (Age 62)
  • Henry J. Fuchs M.D., Executive Vice President and Chief Medical Officer (Age 59)
  • Brian R. Mueller, Group Vice President, Corporate Controller, Chief Accounting Officer (Age 43)
  • Richard A. Meier, Lead Independent Director (Age 57)
  • Willard H. Dere M.D., Independent Director (Age 63)
  • Michael G. Grey, Independent Director

Who owns BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include PRUDENTIAL FINANCIAL INC (6.80%), Jennison Associates LLC (6.72%), Sands Capital Management LLC (4.40%), Palo Alto Investors LLC (1.42%), TIAA CREF Investment Management LLC (0.99%) and Geode Capital Management LLC (0.82%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

Who sold BioMarin Pharmaceutical stock? Who is selling BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Verde Servicos Internacionais S.A., Jennison Associates LLC, William Blair Investment Management LLC, TIAA CREF Investment Management LLC, Sands Capital Management LLC, Strs Ohio, TCW Group Inc. and Eaton Vance Management. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

Who bought BioMarin Pharmaceutical stock? Who is buying BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was bought by a variety of institutional investors in the last quarter, including American Century Companies Inc., Carillon Tower Advisers Inc., Millennium Management LLC, Element Capital Management LLC, Bain Capital Public Equity Management LLC, Employees Retirement System of Texas, UBS Asset Management Americas Inc. and Frontier Capital Management Co. LLC. View Insider Buying and Selling for BioMarin Pharmaceutical.

How do I buy BioMarin Pharmaceutical stock?

Shares of BioMarin Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BioMarin Pharmaceutical stock can currently be purchased for approximately $83.05.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $14.42 billion and generates $1.31 billion in revenue each year. The biotechnology company earns $-630,210,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. BioMarin Pharmaceutical employs 2,293 workers across the globe.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 105 Digital Dr, NOVATO, CA 94949-8703, United States. The biotechnology company can be reached via phone at +1-415-5066700 or via email at [email protected]


MarketBeat Community Rating for BioMarin Pharmaceutical (BMRN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  926 (Vote Outperform)
Underperform Votes:  437 (Vote Underperform)
Total Votes:  1,363
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioMarin Pharmaceutical (NASDAQ:BMRN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.812.732.67
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $113.63$114.00$113.52$111.63
Price Target Upside: 35.28% upside23.39% upside39.45% upside36.34% upside

BioMarin Pharmaceutical (NASDAQ:BMRN) Consensus Price Target History

Price Target History for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2018Morgan StanleyLower Price TargetOverweight -> Overweight$115.00 -> $112.00MediumView Rating Details
2/23/2018Stifel NicolausLower Price TargetBuy -> Buy$105.00 -> $102.00HighView Rating Details
2/23/2018Leerink SwannLower Price TargetOutperform -> Outperform$142.00 -> $132.00HighView Rating Details
2/23/2018BMO Capital MarketsBoost Price TargetOutperform -> Outperform$119.00 -> $125.00HighView Rating Details
2/23/2018Deutsche BankSet Price TargetBuy -> Buy$119.00 -> $124.00HighView Rating Details
1/24/2018JPMorgan Chase & Co.Lower Price TargetOverweight -> Outperform$131.00 -> $129.00MediumView Rating Details
1/18/2018Piper Jaffray CompaniesReiterated RatingBuy$114.00LowView Rating Details
1/18/2018Credit Suisse GroupReiterated RatingOutperform -> Outperform$113.00LowView Rating Details
12/22/2017WedbushReiterated RatingOutperform$110.00MediumView Rating Details
12/15/2017Goldman Sachs GroupUpgradeBuy -> Conviction-BuyHighView Rating Details
12/11/2017SunTrust BanksBoost Price TargetBuy$130.00HighView Rating Details
9/26/2017Jefferies GroupReiterated RatingBuy$116.00LowView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform -> Sector Perform$93.00MediumView Rating Details
8/31/2017CitigroupInitiated CoverageBuy -> Buy$98.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$100.00HighView Rating Details
8/4/2017CowenReiterated RatingBuyLowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$89.00HighView Rating Details
7/22/2017BarclaysReiterated RatingEqual Weight$105.00 -> $100.00LowView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$93.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
2/10/2017GabelliReiterated RatingBuyN/AView Rating Details
1/9/2017Robert W. BairdSet Price TargetBuy$115.00N/AView Rating Details
7/28/2016William BlairSet Price TargetBuy$116.00N/AView Rating Details
6/20/2016OppenheimerReiterated RatingMarket Perform$99.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

BioMarin Pharmaceutical (NASDAQ:BMRN) Earnings History and Estimates Chart

Earnings by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ BMRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018        
10/26/2017Q3 2017($0.13)($0.07)$347.38 million$334.18 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.22)($0.21)$311.41 million$317.50 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.30)$0.03$292.58 million$303.70 millionViewListenView Earnings Details
2/23/2017Q416($0.38)($0.53)$296.54 million$300.00 millionViewN/AView Earnings Details
10/27/2016Q316($0.39)($0.13)$289.70 million$279.90 millionViewListenView Earnings Details
8/4/2016Q216($0.52)($2.61)$278.75 million$300.10 millionViewN/AView Earnings Details
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details
8/3/2015Q215($0.53)($0.22)$218.16 million$250.50 millionViewN/AView Earnings Details
4/30/2015Q1($0.53)($0.25)$204.58 million$203.26 millionViewN/AView Earnings Details
2/25/2015Q414($0.59)($0.30)$189.01 million$230.90 millionViewN/AView Earnings Details
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details
7/30/2014Q214($0.42)($0.19)$159.70 million$191.70 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.50)($0.27)$145.16 million$151.60 millionViewN/AView Earnings Details
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details
4/28/2011($0.10)$0.14ViewN/AView Earnings Details
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.02)($0.03)ViewN/AView Earnings Details
8/2/2010Q2 2010$0.02($0.01)ViewN/AView Earnings Details
4/29/2010Q1 2010$0.01ViewN/AView Earnings Details
2/23/2010Q4 2009$0.05ViewN/AView Earnings Details
10/28/2009Q3 2009$0.06ViewN/AView Earnings Details
4/30/2009Q1 2009($0.12)($0.13)ViewN/AView Earnings Details
2/18/2009Q4 2008$0.24$0.24ViewN/AView Earnings Details
10/28/2008Q3 2008$0.03$0.01ViewN/AView Earnings Details
8/5/2008Q2 2008$0.02$0.04ViewN/AView Earnings Details
4/29/2008Q1 2008($0.04)$0.02ViewN/AView Earnings Details
2/26/2008Q4 2007$0.04$0.03ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

BioMarin Pharmaceutical (NASDAQ:BMRN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.18)$0.17($0.07)
Q2 20183($0.19)($0.02)($0.09)
Q3 20184($0.12)($0.04)($0.09)
Q4 20183($0.20)$0.02($0.08)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

BioMarin Pharmaceutical (NASDAQ BMRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.85%
Institutional Ownership Percentage: 98.77%
Insider Trades by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ BMRN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Jean Jacques BienaimeCEOSell10,000$84.63$846,300.00View SEC Filing  
2/1/2018George Eric DavisEVPSell30,000$90.66$2,719,800.00112,942View SEC Filing  
1/5/2018Jean Jacques BienaimeCEOSell10,000$90.32$903,200.00235,894View SEC Filing  
1/2/2018Henry J. FuchsInsiderSell15,000$89.23$1,338,450.00View SEC Filing  
1/2/2018V Bryan LawlisDirectorSell3,750$88.84$333,150.00View SEC Filing  
12/29/2017Jean Jacques BienaimeCEOSell20,000$89.75$1,795,000.00View SEC Filing  
12/29/2017Jean Jacques BienaimeCEOSell10,000$89.61$896,100.00226,494View SEC Filing  
12/14/2017Elaine J HeronDirectorSell800$88.90$71,120.0038,385View SEC Filing  
11/30/2017George Eric DavisEVPSell1,200$85.64$102,768.00View SEC Filing  
9/28/2017Robert BaffiEVPSell18,415$92.43$1,702,098.45129,083View SEC Filing  
9/22/2017Jeffrey Robert AjerEVPSell3,521$95.00$334,495.0049,299View SEC Filing  
9/15/2017Henry J FuchsInsiderSell15,000$90.50$1,357,500.00141,422View SEC Filing  
9/15/2017V Bryan LawlisDirectorSell3,750$91.26$342,225.0019,660View SEC Filing  
6/23/2017George Eric DavisEVPSell9,844$96.60$950,930.4093,425View SEC Filing  
6/22/2017Brian MuellerSVPSell2,671$100.00$267,100.0015,556View SEC Filing  
6/19/2017Henry J FuchsInsiderSell15,000$90.00$1,350,000.00141,422View SEC Filing  
6/16/2017V Bryan LawlisDirectorSell3,750$90.00$337,500.0019,660View SEC Filing  
6/7/2017Jeffrey Robert AjerEVPSell1,004$89.61$89,968.4447,944View SEC Filing  
6/5/2017George Eric DavisEVPSell9,471$91.04$862,239.8474,342View SEC Filing  
6/5/2017Jean Jacques BienaimeCEOSell10,000$90.13$901,300.00238,564View SEC Filing  
5/24/2017Jean Jacques BienaimeCEOSell5,000$88.38$441,900.00238,564View SEC Filing  
5/17/2017Jean Jacques BienaimeCEOSell5,000$91.73$458,650.00238,564View SEC Filing  
5/8/2017Brian MuellerSVPSell7,482$91.87$687,371.3418,350View SEC Filing  
5/8/2017Jean Jacques BienaimeCEOSell10,000$96.09$960,900.00238,496View SEC Filing  
5/5/2017George Eric DavisEVPSell2,500$100.34$250,850.0085,251View SEC Filing  
5/2/2017Jeffrey Robert AjerEVPSell302$96.74$29,215.4851,834View SEC Filing  
4/27/2017Jean Jacques BienaimeCEOSell5,000$95.72$478,600.00243,194View SEC Filing  
4/25/2017Jean Jacques BienaimeCEOSell5,000$94.00$470,000.00243,194View SEC Filing  
3/29/2017Jeffrey Robert AjerEVPSell3,890$89.15$346,793.5051,532View SEC Filing  
3/16/2017Daniel K SpiegelmanCFOSell1,989$91.96$182,908.4416,460View SEC Filing  
3/16/2017George Eric DavisEVPSell2,238$91.96$205,806.4875,967View SEC Filing  
3/16/2017Jean Jacques BienaimeCEOSell10,000$91.69$916,900.00211,364View SEC Filing  
3/10/2017Jean Jacques BienaimeCEOSell11,000$90.59$996,490.00212,364View SEC Filing  
3/7/2017Jeffrey Robert AjerEVPSell5,000$90.56$452,800.0046,510View SEC Filing  
3/6/2017Daniel K SpiegelmanCFOSell2,303$93.32$214,915.9620,761View SEC Filing  
3/6/2017George Eric DavisEVPSell1,498$93.32$139,793.3678,962View SEC Filing  
3/1/2017Daniel K SpiegelmanCFOSell35,000$94.07$3,292,450.0060,347View SEC Filing  
3/1/2017V Bryan LawlisDirectorSell7,500$95.00$712,500.0021,360View SEC Filing  
2/24/2017Henry J FuchsInsiderSell15,000$87.99$1,319,850.00128,442View SEC Filing  
1/26/2017Jean Jacques BienaimeCEOSell10,000$84.22$842,200.00175,682View SEC Filing  
1/11/2017Jean Jacques BienaimeCEOSell8,000$90.58$724,640.00174,682View SEC Filing  
1/9/2017Daniel K SpiegelmanCFOSell5,000$90.00$450,000.0018,100View SEC Filing  
1/9/2017Jean Jacques BienaimeCEOSell8,000$88.49$707,920.00174,682View SEC Filing  
12/30/2016Jean Jacques BienaimeCEOSell8,000$83.60$668,800.00174,682View SEC Filing  
11/22/2016Jean Jacques BienaimeCEOSell69,743$85.69$5,976,277.67View SEC Filing  
11/21/2016Jean Jacques BienaimeCEOSell69,744$87.56$6,106,784.64View SEC Filing  
11/8/2016Jean Jacques BienaimeCEOSell140,000$82.67$11,573,800.00393,368View SEC Filing  
11/7/2016Jean Jacques BienaimeCEOSell70,000$82.52$5,776,400.00393,368View SEC Filing  
10/28/2016Jean Jacques BienaimeCEOSell120,000$81.30$9,756,000.00383,368View SEC Filing  
10/17/2016Jean Jacques BienaimeCEOSell41,666$84.39$3,516,193.74365,034View SEC Filing  
10/14/2016Jean Jacques BienaimeCEOSell64,125$86.96$5,576,310.00378,184View SEC Filing  
9/29/2016Jean Jacques BienaimeCEOSell53,125$93.65$4,975,156.25431,709View SEC Filing  
9/27/2016Jeffrey Robert AjerEVPSell18,467$95.61$1,765,629.8741,342View SEC Filing  
9/16/2016Jean Jacques BienaimeCEOSell137,368$95.34$13,096,665.12421,161View SEC Filing  
8/26/2016Henry J FuchsEVPSell15,000$95.06$1,425,900.00128,878View SEC Filing  
8/16/2016Jean Jacques BienaimeCEOSell41,666$91.49$3,812,022.34420,250View SEC Filing  
8/1/2016Brian MuellerVPSell287$100.00$28,700.0014,260View SEC Filing  
8/1/2016Daniel K SpiegelmanCFOSell4,000$99.33$397,320.0042,944View SEC Filing  
8/1/2016George Eric DavisEVPSell2,167$100.00$216,700.0071,158View SEC Filing  
7/27/2016V Bryan LawlisDirectorSell1,100$95.39$104,929.0014,960View SEC Filing  
7/22/2016V Bryan LawlisDirectorSell6,400$95.01$608,064.0020,260View SEC Filing  
7/18/2016Jean Jacques BienaimeCEOSell41,666$92.72$3,863,271.52420,250View SEC Filing  
7/7/2016George Eric DavisEVPSell2,167$90.00$195,030.0072,836View SEC Filing  
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.5013,860View SEC Filing  
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30420,250View SEC Filing  
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.8646,944View SEC Filing  
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.0871,235View SEC Filing  
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00130,914View SEC Filing  
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.8358,644View SEC Filing  
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00130,386View SEC Filing  
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.3891,894View SEC Filing  
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00390,156View SEC Filing  
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.4563,487View SEC Filing  
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00395,635View SEC Filing  
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.1676,190View SEC Filing  
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.1048,137View SEC Filing  
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.7654,311View SEC Filing  
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00350,500View SEC Filing  
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.0033,750View SEC Filing  
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.0066,156View SEC Filing  
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00228,754View SEC Filing  
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.0028,229View SEC Filing  
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.0011,850View SEC Filing  
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00228,754View SEC Filing  
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00228,754View SEC Filing  
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00180,257View SEC Filing  
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55180,257View SEC Filing  
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.0460,950View SEC Filing  
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.6420,980View SEC Filing  
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.009,700View SEC Filing  
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.8264,850View SEC Filing  
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.8967,850View SEC Filing  
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.0042,350View SEC Filing  
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.0043,266View SEC Filing  
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioMarin Pharmaceutical (NASDAQ BMRN) News Headlines

Source:
DateHeadline
Head-To-Head Comparison: Avid Bioservices (CDMO) versus BioMarin Pharmaceutical (BMRN)Head-To-Head Comparison: Avid Bioservices (CDMO) versus BioMarin Pharmaceutical (BMRN)
www.americanbankingnews.com - February 24 at 1:06 AM
BioMarin Pharmaceutical (BMRN) Price Target Cut to $102.00 by Analysts at Stifel NicolausBioMarin Pharmaceutical (BMRN) Price Target Cut to $102.00 by Analysts at Stifel Nicolaus
www.americanbankingnews.com - February 23 at 9:10 PM
BioMarin Pharmaceutical (BMRN) PT Set at $124.00 by Deutsche BankBioMarin Pharmaceutical (BMRN) PT Set at $124.00 by Deutsche Bank
www.americanbankingnews.com - February 23 at 9:10 PM
BMO Capital Markets Increases BioMarin Pharmaceutical (BMRN) Price Target to $125.00BMO Capital Markets Increases BioMarin Pharmaceutical (BMRN) Price Target to $125.00
www.americanbankingnews.com - February 23 at 9:10 PM
BioMarin Pharmaceutical (BMRN) Given New $132.00 Price Target at Leerink SwannBioMarin Pharmaceutical (BMRN) Given New $132.00 Price Target at Leerink Swann
www.americanbankingnews.com - February 23 at 9:10 PM
Morgan Stanley Cuts BioMarin Pharmaceutical (BMRN) Price Target to $112.00Morgan Stanley Cuts BioMarin Pharmaceutical (BMRN) Price Target to $112.00
www.americanbankingnews.com - February 23 at 8:00 PM
Why Leerink Adjusted Upside Expectations For 3 Biotechs - BenzingaWhy Leerink Adjusted Upside Expectations For 3 Biotechs - Benzinga
www.benzinga.com - February 23 at 4:28 PM
BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat - NasdaqBioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat - Nasdaq
www.nasdaq.com - February 23 at 4:28 PM
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $100 at Citi Following 4Q - StreetInsider.comBioMarin Pharmaceutical Inc. (BMRN) PT Raised to $100 at Citi Following 4Q - StreetInsider.com
www.streetinsider.com - February 23 at 4:28 PM
Is This Biotech Hedging Its 2018 Outlook On A Key FDA Approval?Is This Biotech Hedging Its 2018 Outlook On A Key FDA Approval?
finance.yahoo.com - February 23 at 4:28 PM
Why Leerink Adjusted Upside Expectations For 3 BiotechsWhy Leerink Adjusted Upside Expectations For 3 Biotechs
finance.yahoo.com - February 23 at 4:28 PM
Comparing ChemoCentryx (CCXI) & BioMarin Pharmaceutical (BMRN)Comparing ChemoCentryx (CCXI) & BioMarin Pharmaceutical (BMRN)
www.americanbankingnews.com - February 23 at 2:20 PM
BioMarin Pharmaceutical (BMRN) Q4 2017 Results - Earnings Call TranscriptBioMarin Pharmaceutical (BMRN) Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - February 23 at 9:51 AM
BioMarin Announces Fourth Quarter and Full Year 2017 Financial ResultsBioMarin Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 23 at 9:51 AM
BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales BeatBioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat
finance.yahoo.com - February 23 at 9:51 AM
BioMarin Pharmaceutical (BMRN) Issues Quarterly  Earnings ResultsBioMarin Pharmaceutical (BMRN) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 22 at 8:34 PM
BioMarin Pharmaceutical Inc. to Host Earnings CallBioMarin Pharmaceutical Inc. to Host Earnings Call
finance.yahoo.com - February 22 at 4:28 PM
Biomarin Pharmaceutical Q4 Earnings OutlookBiomarin Pharmaceutical Q4 Earnings Outlook
finance.yahoo.com - February 22 at 4:28 PM
 Brokerages Anticipate BioMarin Pharmaceutical Inc. (BMRN) Will Announce Quarterly Sales of $346.24 Million Brokerages Anticipate BioMarin Pharmaceutical Inc. (BMRN) Will Announce Quarterly Sales of $346.24 Million
www.americanbankingnews.com - February 21 at 7:48 AM
Jean Jacques Bienaime Sells 10,000 Shares of BioMarin Pharmaceutical Inc. (BMRN) StockJean Jacques Bienaime Sells 10,000 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock
www.americanbankingnews.com - February 20 at 9:12 PM
What to Expect From BioMarin (BMRN) This Earnings Season?What to Expect From BioMarin (BMRN) This Earnings Season?
www.zacks.com - February 20 at 9:12 AM
More Health Care Catalysts to Watch For by the End of FebruaryMore Health Care Catalysts to Watch For by the End of February
www.msn.com - February 19 at 4:22 PM
BioMarin Pharmaceutical Inc. (BMRN) Expected to Announce Earnings of -$0.24 Per ShareBioMarin Pharmaceutical Inc. (BMRN) Expected to Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - February 19 at 12:16 PM
Catalyst Pharmaceuticals Gets Positive FDA Advise On Firdapse NDA RefilingCatalyst Pharmaceuticals Gets Positive FDA Advise On Firdapse NDA Refiling
www.benzinga.com - February 15 at 4:28 PM
Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling - NasdaqCatalyst Gets Positive FDA Advise on Firdapse NDA Refiling - Nasdaq
www.nasdaq.com - February 15 at 6:22 AM
BioMarin Pharmaceutical (BMRN) to Release Earnings on ThursdayBioMarin Pharmaceutical (BMRN) to Release Earnings on Thursday
www.americanbankingnews.com - February 15 at 1:26 AM
BioMarin Pharmaceutical Inc. (BMRN) Receives Average Rating of "Buy" from AnalystsBioMarin Pharmaceutical Inc. (BMRN) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 14 at 3:42 PM
Wedbush Weighs in on BioMarin Pharmaceutical Inc.s FY2022 Earnings (BMRN)Wedbush Weighs in on BioMarin Pharmaceutical Inc.'s FY2022 Earnings (BMRN)
www.americanbankingnews.com - February 9 at 6:30 PM
WORLDSymposium Recognizes BioMarins Brineura® (cerliponase alfa) with 2018 New Treatment AwardWORLDSymposium Recognizes BioMarin's Brineura® (cerliponase alfa) with 2018 New Treatment Award
finance.yahoo.com - February 8 at 3:23 PM
BioMarin Pharma (BMRN) Announced Interim Data of Phase 1/2 ... - StreetInsider.comBioMarin Pharma (BMRN) Announced Interim Data of Phase 1/2 ... - StreetInsider.com
www.streetinsider.com - February 8 at 6:08 AM
BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at WORLDSymposium™ 2018BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at WORLDSymposium™ 2018
finance.yahoo.com - February 8 at 6:08 AM
BioMarin Announces 20 Presentations at 14th Annual WORLDSymposium™ 2018BioMarin Announces 20 Presentations at 14th Annual WORLDSymposium™ 2018
finance.yahoo.com - February 6 at 6:12 AM
George Eric Davis Sells 30,000 Shares of BioMarin Pharmaceutical Inc. (BMRN) StockGeorge Eric Davis Sells 30,000 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock
www.americanbankingnews.com - February 5 at 9:14 PM
5 Top Stocks With 100% Buy Ratings Right Now5 Top Stocks With 100% Buy Ratings Right Now
finance.yahoo.com - February 4 at 3:25 PM
5 Top Stocks With 100% Buy Ratings Right Now5 Top Stocks With 100% Buy Ratings Right Now
finance.yahoo.com - February 4 at 3:25 PM
$346.24 Million in Sales Expected for BioMarin Pharmaceutical Inc. (BMRN) This Quarter$346.24 Million in Sales Expected for BioMarin Pharmaceutical Inc. (BMRN) This Quarter
www.americanbankingnews.com - February 4 at 4:56 AM
How Biogen’s Spinraza Is Positioned for 2018How Biogen’s Spinraza Is Positioned for 2018
finance.yahoo.com - February 2 at 3:23 PM
BioMarin Pharmaceutical Inc. (BMRN) Expected to Announce Earnings of -$0.23 Per ShareBioMarin Pharmaceutical Inc. (BMRN) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - February 2 at 2:22 PM
Biotech Stocks Research Reports Released on Bioverativ, BioMarin Pharma, Blueprint Medicines, and Concordia Intl. - PR Newswire (press release)Biotech Stocks' Research Reports Released on Bioverativ, BioMarin Pharma, Blueprint Medicines, and Concordia Intl. - PR Newswire (press release)
www.prnewswire.com - January 31 at 6:16 AM
How a drug maker and a genetic test company are teaming up against a child killer - San Francisco Business TimesHow a drug maker and a genetic test company are teaming up against a child killer - San Francisco Business Times
www.bizjournals.com - January 30 at 6:16 AM
Critical Survey: BioMarin Pharmaceutical (BMRN) vs. Ocera Therapeutics (OCRX)Critical Survey: BioMarin Pharmaceutical (BMRN) vs. Ocera Therapeutics (OCRX)
www.americanbankingnews.com - January 29 at 3:16 AM
BioMarin Pharmaceutical (BMRN) Price Target Lowered to $129.00 at JPMorgan Chase & Co.BioMarin Pharmaceutical (BMRN) Price Target Lowered to $129.00 at JPMorgan Chase & Co.
www.americanbankingnews.com - January 28 at 2:22 PM
5 Biotechs That May Surge On Takeovers - Investopedia (blog)5 Biotechs That May Surge On Takeovers - Investopedia (blog)
www.investopedia.com - January 27 at 6:19 AM
BioMarin Pharmaceutical (BMRN) vs. Syndax Pharmaceuticals (SNDX) Financial ContrastBioMarin Pharmaceutical (BMRN) vs. Syndax Pharmaceuticals (SNDX) Financial Contrast
www.americanbankingnews.com - January 25 at 1:29 PM
Clovis, Incyte And BioMarin Are Todd Hagopians Top Takeover CandidatesClovis, Incyte And BioMarin Are Todd Hagopian's Top Takeover Candidates
finance.yahoo.com - January 24 at 3:25 PM
Will Sanofi's Big Hemophilia Deal Pay Off?Will Sanofi's Big Hemophilia Deal Pay Off?
finance.yahoo.com - January 24 at 9:26 AM
BioMarin to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Thursday, February 22 at 4:30pm ETBioMarin to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Thursday, February 22 at 4:30pm ET
finance.yahoo.com - January 24 at 9:26 AM
FBTs Holdings Imply 17% Gain Potential - NasdaqFBT's Holdings Imply 17% Gain Potential - Nasdaq
www.nasdaq.com - January 22 at 3:28 PM
BioMarin Pharmaceuticals (BMRN) "Outperform" Rating Reaffirmed at Credit Suisse GroupBioMarin Pharmaceutical's (BMRN) "Outperform" Rating Reaffirmed at Credit Suisse Group
www.americanbankingnews.com - January 21 at 5:34 PM
BioMarin Pharmaceutical Inc. (BMRN) Receives Consensus Recommendation of "Buy" from AnalystsBioMarin Pharmaceutical Inc. (BMRN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 20 at 4:22 PM

SEC Filings

BioMarin Pharmaceutical (NASDAQ:BMRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioMarin Pharmaceutical (NASDAQ:BMRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioMarin Pharmaceutical (NASDAQ BMRN) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.